Homepage

R21/Matrix-M™ malaria vaccine developed by University of Oxford receives regulatory clearance for use in Ghana

The University of Oxford-developed and Serum Institute of India PvT Ltd (SIIPL)- manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Ghana by the country’s Food and Drugs Authority.

Prof Adrian Hill, Lakshmi Mittal & Family Professor Of Vaccinology and Director of the Jenner Institute; and Dr César López-Camacho, Senior Researcher and Group Leader for mRNA technologies, with Ms Josefa González-Blanco at the Jenner Institute.

Mexican Ambassador visits Jenner Institute

The Mexican Ambassador to the United Kingdom, Her Excellency Ms Josefa González-Blanco Ortiz Mena, was given a tour and met with representatives of the Jenner Institute.

Romain Guyon awarded 2022 Michelson Prize

DPhil student at the Jenner Institute, Romain Guyon is among the researchers who received the 2022 Michelson Prizes: Next Generation Grants, announced by Michelson Medical Research Foundation and Human Immunome Project.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two NIHR Biomedical Research Centres (BRC). Professor Helen McShane, Director of the NIHR Oxford BRC and Jenner Investigator said: 'This funding is a recognition of the high calibre work done by our researchers in recent years'.

Malaria booster vaccine continues to meet WHO-specified 75% efficacy goal

Illustration showing how the Ebola virus looks under a microscope

Ebola vaccine to begin human trials

The University of Oxford have begun recruiting for a Phase I trial to test an Ebola vaccine in human volunteers – with the first vaccinations having already taken place.

History of the COVID-19 VACCINE

The Oxford / AstraZeneca COVID-19 vaccine is estimated to have saved more than six million lives – more than any other COVID vaccine, during the first year of use. Read more here

SUPPORT OXFORD’S COVID-19 VACCINE RESEARCH

Funding for Oxford’s COVID-19 vaccine research requires unprecedented speed, scope and ambition. Support from Government, corporations, trusts and foundations will be crucial to the development of a vaccine to combat the new virus. Alongside those traditional sources of funding, philanthropic donations of any size will have real and rapid impact, allowing us to accelerate this time-critical research, and ensure that Oxford’s vaccine solution will be as effective and swift as possible.

If you are interested in supporting this effort, please make a gift here.

Latest publications

Salmonella Combination Vaccines: Moving Beyond Typhoid
Journal article

MacLennan CA. et al, (2023), Open Forum Infectious Diseases, 10, S58 - S66
Accelerating clinical development of a live attenuated vaccine against Salmonella Paratyphi A (VASP): study protocol for an observer-participant-blind randomised control trial of a novel oral vaccine using a human challenge model of Salmonella Paratyphi A infection in healthy adult volunteers.
Journal article

McCann N. et al, (2023), BMJ Open, 13

Seminars

Public Engagement